{
    "clinical_study": {
        "@rank": "58826", 
        "arm_group": {
            "arm_group_label": "Parkinson's disease", 
            "description": "Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this registry is to compile characteristics of world-wide outcomes for the\n      use of Boston Scientific's commercially available Vercise DBS system in the treatment of\n      Parkinson's disease."
        }, 
        "brief_title": "Registry of Deep Brain Stimulation With the VERCISE\u2122 System: Vercise DBS Registry", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this registry is to compile characteristics of world-wide outcomes for the\n      use of Boston Scientific's commercially available Vercise DBS system in the treatment of\n      Parkinson's disease.\n\n      Subjects' improvement in disease symptoms and overall Quality of life will be assessed\n      during the study following DBS and compared with baseline."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets criteria established in locally applicable Vercise System Direction for Use\n\n          -  At least 18 years old\n\n        Exclusion Criteria:\n\n          -  Meets any contraindication in the Vercise System locally applicable Directions for\n             Use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with symptoms of Parkinson's disease that are not adequately controlled with\n        medication"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071134", 
            "org_study_id": "A4010"
        }, 
        "intervention": {
            "arm_group_label": "Parkinson's disease", 
            "description": "Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.", 
            "intervention_name": "Deep Brain Stimulation (DBS)", 
            "intervention_type": "Device", 
            "other_name": [
                "Vercise DBS System", 
                "Boston Scientific"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Deep brain stimulation", 
            "Parkinson's disease", 
            "Vercise"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "email": "BSNClinicaltrials@bsci.com", 
                "last_name": "Boston Scientific Clinical Research"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France"
                }, 
                "name": "Boston Scientific International SA"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Registry of Deep Brain Stimulation With the VERCISE\u2122 System: Vercise DBS Registry", 
        "other_outcome": [
            {
                "description": "Change in patient's motor symptoms as determined by UPDRS during the study as compared with baseline", 
                "measure": "Change in parkinson's disease symptoms as determined by UPDRS scores during the study as compared with baseline", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Change in medication usage during the study as compared with baseline", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "Impression of change scores during the study as compared with baseline", 
                "measure": "Impression of change scores during the study as compared with baseline", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "overall_contact": {
            "email": "VanDycKN@bsci.com", 
            "last_name": "Nic Van Dyck", 
            "phone": "31-43-356-8328"
        }, 
        "overall_official": {
            "affiliation": "Boston Scientific Corporation", 
            "last_name": "Roshini Jain", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in quality of life assessments during the study as compared with baseline", 
            "measure": "Improvement in patient's quality of life (QoL) during the study as compared with baseline", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071134"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boston Scientific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Scientific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Years", 
        "verification_date": "February 2014"
    }
}